As the iPSC field continues to evolve and candidates make their way to the clinic, there has never been a more critical time to unite with your peers and take the lead in shaping the future of iPSC drug development!

Participants had the opportunity to join the 3rd Annual iPSC Derived-Cell Therapies Summit, where the brightest minds and leading experts united to benchmark the current bottlenecks in discovery, translation, and clinical strategy. This year's summit had promised to be the largest meeting dedicated solely to iPSC drug development, providing a platform to showcase cutting-edge pre-clinical and brand-new clinical data that are redefining the landscape of cell therapies for oncology and regenerative medicine.

Attendees walked away with a robust understanding of how to ensure the highest quality product covering genetic stability, purified differentiation, and in vivo survivability to secure approvals for their groundbreaking iPSC-derived product. They took home creative approaches and pioneering strategies to elevate their investment appeal, navigate the IND requirements and streamline your clinical pipeline for maximum efficiency. They delved into the latest advancements in safety protocols, regulatory compliance, and approval processes.

Mark your calendars and secure your spot at the flagship Annual iPSC Derived-Cell Therapies Summit next year!